Evidence map›Paper›PMID 18768663›Full record

ArticleJournal of molecular endocrinology2008

Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.

Bin Chen, Yuanzhong Wang, Susan E Kane, Shiuan Chen

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular endocrinology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. 17β-estradiol promotes extracellular vesicle release and selective miRNA loading in ERα-positive breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Letrozole improves the sensitivity of breast cancer cells overexpressing aromatase to cisplatin via down-regulation of FEN1.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2019
    Article
  7. Article
  8. Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HRClinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Bin Chen, Department of Surgical Research Division of Molecular Medicine, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.
Yuanzhong Wang
Susan E Kane
Shiuan Chen
City of Hope · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
AROMATASE AND BREAST CANCERR01CA044735 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI CHEN, SHIUAN · 1988 to 2009
$4.0M
ENDOCRINE DISRUPTING CHEMICALS AND AROMATASER01ES008258 · NIEHS · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI CHEN, SHIUAN · 1996 to 2009
$2.6M
NCI NIH HHS CA33572NCI NIH HHS CA44735NCI NIH HHS P30 CA033572NCI NIH HHS R01 CA044735NIEHS NIH HHS ES08258NIEHS NIH HHS R01 ES008258
6 · The paper itself

Abstract

ERBB2 overexpression in estrogen receptor (ER)-positive breast cancer cells such as BT474 (BT) cells has been found to confer resistance to tamoxifen, and suppression of ERBB2 improves the antiproliferative effects of tamoxifen. In this study, the responsiveness to tamoxifen in the BT/HerR, Herceptin-resistant BT cell lines established through constant Herceptin exposure, was evaluated. Compared with BT cells, improvement of sensitivity to tamoxifen in BT/HerR was demonstrated by ER functional analysis and cell proliferation assay. Tamoxifen in the resistant cell line was found to inhibit 17beta-estradiol-stimulating estrogen-responsive gene pS2 expression more effectively than in BT cells in real-time PCR assay. Western blot analysis showed that cross-phosphorylation between ER and downstream components of ERBB2 was attenuated in BT/HerR cells. ER redistribution from cytoplasm to nucleus could be found in these cells through immunofluorescence and confocal studies, and importantly, chromatin immunoprecipitation studies demonstrated that tamoxifen induced occupancy of the pS2 promoter by ER and nuclear receptor corepressor (NCOR1) instead of coactivator NCOA3 in these cells. Finally, combination of tamoxifen and Herceptin was found to improve the sensitivity of BT/HerR cells to Herceptin. Our results suggest that the ER genomic pathway in the ER-positive and Herceptin-resistant breast cancer cells may be reactivated, allowing tamoxifen therapy to be effective again, and a combination of tamoxifen and Herceptin can be a potential therapeutic strategy for ER-positive and Herceptin-resistant human breast cancer.

Indexed as

Drug Resistance, NeoplasmAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsBreast NeoplasmsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleHistone AcetyltransferasesHumansNuclear Receptor Coactivator 1Protein IsoformsReceptors, EstrogenSignal TransductionTamoxifenTranscription FactorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsErb-b2 Receptor Tyrosine KinasesHistone AcetyltransferasesNCOA1 protein, humanNuclear Receptor Coactivator 1Protein IsoformsReceptors, EstrogenTamoxifenTranscription FactorsTrastuzumab

Identifiers

PMID18768663
PMCPMC3503452
OpenAlexW2116987618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.